Texas is currently home to 4876 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Recruiting
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Invasive Breast Carcinoma
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Recruiting
This phase II trial studies methylprednisolone, horse anti-thymocyte globulin, cyclosporine, filgrastim, and/or pegfilgrastim or pegfilgrastim biosimilar in treating patients with aplastic anemia or low or intermediate-risk myelodysplastic syndrome. Horse anti-thymocyte globulin is made from horse blood and targets immune cells known as T-lymphocytes. Since T-lymphocytes are believed to be involved in causing low blood counts in aplastic anemia and in some cases of myelodysplastic syndromes, kil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruiting
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Gemtuz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
04/21/2025
Locations: Investigative Site, Cypress, Texas
Conditions: Parkinson Disease
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Recruiting
This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with moderate-to-severe atopic dermatitis (AD). This study explores the efficacy and safety of 3 subcutaneous (SC) dose regimens of lunsekimig in adult participants with moderate-to-severe AD who have a documented history, within 6 months prior to baseline, of an inadequate... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/21/2025
Locations: DermResearch-Site Number: 8400014, Austin, Texas
Conditions: Dermatitis Atopic
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
Recruiting
An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopalâ„¢ XRT in patients with metastatic solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Malignancies
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
Recruiting
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/21/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: HIV Infections
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
Recruiting
The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: JPS Health Network/Acclaim Multispecialty Clinic, Fort Worth, Texas
Conditions: Venous Leg Ulcer (VLU)
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: The University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced or Metastatic Solid Tumors
Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency
Recruiting
A non-randomized, open-label, dose escalation study of a single intracerebroventricular (ICV) administration of a gene replacement therapy in subjects who are 2 to 18 years old with NGLY1 Deficiency.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
04/21/2025
Locations: Texas Children's Hospital (Baylor College of Medicine), Houston, Texas
Conditions: NGLY1 Deficiency
Targeting Social Function in Anxiety and Eating Disorders
Recruiting
Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task.... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/21/2025
Locations: UT Southwestern Multispecialty Psychiatry Clinic, Dallas, Texas
Conditions: Eating Disorders, Anorexia Nervosa, Bulimia Nervosa, Atypical Anorexia Nervosa, Purging (Eating Disorders), Other Specified Feeding or Eating Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Recruiting
Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancers